NCT01081951Active, not recruitingPhase 2
Study to Compare the Efficacy and Safety of Olaparib When Given in Combination With Carboplatin and Paclitaxel, Compared With Carboplatin and Paclitaxel in Patients With Advanced Ovarian Cancer
A Phase II Open Label Randomised Comparative Multicentre Study to Compare the Efficacy and Tolerability of Olaparib in Combination With Paclitaxel and Carboplatin Versus Paclitaxel and Carboplatin Alone in Patients With Platinum Sensitive Advanced Serous Ovarian Cancer
Source: ClinicalTrials.gov · Last updated 5 Aug 2026
Brief summary (registry, in English)
To compare the efficacy of olaparib in combination with paclitaxel and carboplatin (AUC4) when compared with carboplatin (AUC6) and paclitaxel alone in patients with advanced ovarian cancer.
- Status (registry)
- Active, not recruiting
- Phase (registry)
- Phase 2
- Study type
- Interventional
- Enrollment
- 162 (actual)
- First submitted
- 26 Feb 2010
- Start date
- 4 Feb 2010
- Primary completion date
- 10 Oct 2011
- Lead sponsor
- AstraZeneca
- Diseases
- Ovarian cancer
- NCT number
- NCT01081951
- EudraCT number
- 2009-015970-36
What you commit to
- Study type: Interventional · Phase 2
- Participants enrolled: 162
- From 4 Feb 2010 to the primary completion date, 10 Oct 2011
- 48 sites in 13 countries
- Visits and tests: ask the trial team, the registry does not list them
Built from the registry fields of ClinicalTrials.gov. It describes the study, not your situation.
Who cannot take part
Copied verbatim from ClinicalTrials.gov and grouped by topic. Only the trial team decides who can take part.
Prior treatment
- Patients receiving any systemic anticancer chemotherapy, radiotherapy (except palliative) within two weeks from the last dose prior to study treatment
- Hypersensitivity to pre medications required for treatment with paclitaxel/carboplatin
Who the study is looking for
- Diagnosed with serous ovarian cancer
- Patients who have received no more than 3 previous platinum containing treatments and were progression free for at least 6 months following the end of the last platinum treatment
- At least one lesion that is suitable for accurate repeated measurements
Age in the registry: 18 years to 125 years · Sex: Female · Does not accept healthy volunteers
Sites (48)
Sites in registry order. Pick your city on the disease page to sort them by distance.
This page is information, not medical advice. Discuss any trial with your doctor.